[go: up one dir, main page]

CL2012001597A1 - Formulacion farmaceutica que comprende ranolazina y dronedarona o una sal de esta, y un portador farmaceuticamente aceptable; util para tratar fibrilacion auricular. - Google Patents

Formulacion farmaceutica que comprende ranolazina y dronedarona o una sal de esta, y un portador farmaceuticamente aceptable; util para tratar fibrilacion auricular.

Info

Publication number
CL2012001597A1
CL2012001597A1 CL2012001597A CL2012001597A CL2012001597A1 CL 2012001597 A1 CL2012001597 A1 CL 2012001597A1 CL 2012001597 A CL2012001597 A CL 2012001597A CL 2012001597 A CL2012001597 A CL 2012001597A CL 2012001597 A1 CL2012001597 A1 CL 2012001597A1
Authority
CL
Chile
Prior art keywords
ranolazine
dronedarone
salt
pharmaceutically acceptable
acceptable carrier
Prior art date
Application number
CL2012001597A
Other languages
English (en)
Inventor
Charles Antzelevitch
Luiz Belardinelli
Dewan Zeng
Alexander Burashnikov
John Shryock
Original Assignee
Gilead Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43736345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001597(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Science Inc filed Critical Gilead Science Inc
Publication of CL2012001597A1 publication Critical patent/CL2012001597A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Método para tratar o prevenir fibrilación auricular y/o aleteo auricular que comprende administrar dronedarona y ranolazina o una de sus sales; formulación farmacéutica que comprende ranolazina y dronedarona o una sal de éstas, y un portador farmacéuticamente aceptable.
CL2012001597A 2009-12-21 2012-06-14 Formulacion farmaceutica que comprende ranolazina y dronedarona o una sal de esta, y un portador farmaceuticamente aceptable; util para tratar fibrilacion auricular. CL2012001597A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28873909P 2009-12-21 2009-12-21

Publications (1)

Publication Number Publication Date
CL2012001597A1 true CL2012001597A1 (es) 2013-06-28

Family

ID=43736345

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001597A CL2012001597A1 (es) 2009-12-21 2012-06-14 Formulacion farmaceutica que comprende ranolazina y dronedarona o una sal de esta, y un portador farmaceuticamente aceptable; util para tratar fibrilacion auricular.

Country Status (36)

Country Link
US (3) US8513254B2 (es)
EP (2) EP2515900B1 (es)
JP (2) JP5723889B2 (es)
KR (2) KR20160108611A (es)
CN (3) CN102665713B (es)
AP (1) AP3536A (es)
AR (1) AR079552A1 (es)
AU (1) AU2010339753B2 (es)
BR (1) BR112012015499A2 (es)
CA (1) CA2784028C (es)
CL (1) CL2012001597A1 (es)
CR (1) CR20120353A (es)
CY (1) CY1116511T1 (es)
DK (1) DK2515900T3 (es)
EA (2) EA025445B1 (es)
EC (1) ECSP12012004A (es)
ES (2) ES2646603T3 (es)
HR (1) HRP20150644T1 (es)
HU (1) HUE026916T2 (es)
IL (1) IL220152A (es)
ME (1) ME02179B (es)
MX (2) MX344329B (es)
NO (1) NO2749282T3 (es)
NZ (2) NZ627181A (es)
PE (1) PE20121520A1 (es)
PL (2) PL2515900T3 (es)
PT (2) PT2515900E (es)
RS (1) RS54118B1 (es)
SG (3) SG181541A1 (es)
SI (2) SI2515900T1 (es)
SM (1) SMT201500171B (es)
TW (1) TWI508726B (es)
UA (1) UA109887C2 (es)
UY (1) UY33119A (es)
WO (1) WO2011084733A1 (es)
ZA (1) ZA201204608B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL165304A0 (en) 2002-05-21 2006-01-15 Cv Therapeutics Inc Method of treating diabetes
EA025824B1 (ru) * 2009-07-27 2017-02-28 Джилид Сайэнс, Инк. Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
CN102724946B (zh) 2009-07-29 2015-06-10 Icu医学有限公司 流体传输装置及使用方法
WO2011135582A2 (en) * 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of dronedarone
ES2529119T3 (es) 2010-07-02 2015-02-17 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de canales iónicos
KR20140033377A (ko) 2011-05-10 2014-03-18 길리애드 사이언시즈, 인코포레이티드 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
NO3175985T3 (es) 2011-07-01 2018-04-28
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
AU2013203252B2 (en) * 2012-01-27 2015-08-20 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
US20140364417A1 (en) * 2013-05-03 2014-12-11 Gilead Sciences, Inc. Method of treating atrial fibrillation
WO2015017441A1 (en) * 2013-08-02 2015-02-05 Gilead Sciences, Inc. Pharmaceutical compositions of ranolazine and dronedarone
US9932588B2 (en) * 2013-11-15 2018-04-03 Northwestern University Inhibition of oxidative stress in atrial fibrillation
AU2014364783B2 (en) 2013-12-19 2017-01-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
CN104951870B (zh) * 2015-06-01 2018-11-13 南通科瑞斯生物医药科技有限公司 药物临床前心脏风险评估方法
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
CA3016081A1 (en) 2016-03-04 2017-09-08 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
US10575744B2 (en) 2017-02-24 2020-03-03 Medtronic Cryocath Lp Pericardial balloon mapping
US10799703B2 (en) * 2017-12-22 2020-10-13 Medtronic, Inc. Evaluation of his bundle pacing therapy
EP3530182B1 (en) * 2018-02-27 2020-12-09 Nokia Technologies Oy Apparatus and method for determining a change in left ventricular twist of a subject's heart
CA3216031A1 (en) * 2018-07-16 2020-01-23 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
AU2020212054B2 (en) * 2019-01-24 2025-06-12 Northwestern University Gene therapy treatment of atrial fibrillation
TW202342447A (zh) 2021-12-03 2023-11-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物
FI4440702T3 (fi) 2021-12-03 2025-08-08 Gilead Sciences Inc Terapeuttisia yhdisteitä hiv-virusinfektiota varten

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
ATE223218T1 (de) 1989-06-23 2002-09-15 Syntex Llc Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
ZA953078B (en) 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
FR2764800B1 (fr) 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
AU2001278045B2 (en) 2000-07-27 2006-08-03 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
FR2817750B1 (fr) 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
DE60117857D1 (de) 2000-12-27 2006-05-04 Genzyme Corp Kontrollierte freisetzung von anti-arrhythmica aus einem biodegradierbaren hydrogel für die lokale anwendung am herzen
US20050065208A1 (en) 2001-07-20 2005-03-24 Bodo Brandts Benzofuranes and their use in the treatment of atrial fibrillation
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
RU2384332C2 (ru) 2005-01-06 2010-03-20 Си Ви Терапьютикс, Инк. Фармацевтические препаративные формы замедленного высвобождения
WO2007053610A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
EP2136780A1 (en) 2007-02-13 2009-12-30 CV Therapeutics Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090247535A1 (en) 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
EP2133074A1 (en) * 2008-06-10 2009-12-16 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation
US20100056536A1 (en) 2008-09-04 2010-03-04 Charles Antzelevitch Method of treating atrial fibrillation

Also Published As

Publication number Publication date
EA201290451A1 (ru) 2013-01-30
MX344329B (es) 2016-12-13
JP5723889B2 (ja) 2015-05-27
AU2010339753B2 (en) 2015-01-22
NZ600718A (en) 2014-08-29
PE20121520A1 (es) 2012-11-26
SMT201500171B (it) 2015-09-07
AR079552A1 (es) 2012-02-01
CA2784028A1 (en) 2011-07-14
EA201691336A1 (ru) 2017-05-31
TW201136586A (en) 2011-11-01
AU2010339753A1 (en) 2012-07-12
EP2515900A1 (en) 2012-10-31
AP3536A (en) 2016-01-13
CN104688739A (zh) 2015-06-10
IL220152A (en) 2016-11-30
US8513254B2 (en) 2013-08-20
SI2749282T1 (sl) 2017-12-29
PL2749282T3 (pl) 2018-01-31
ME02179B (me) 2015-10-20
KR20160108611A (ko) 2016-09-19
NO2749282T3 (es) 2018-01-06
CR20120353A (es) 2014-10-07
EP2749282A1 (en) 2014-07-02
UA109887C2 (uk) 2015-10-26
KR20120107995A (ko) 2012-10-04
BR112012015499A2 (pt) 2016-05-03
HRP20150644T1 (hr) 2015-07-31
WO2011084733A1 (en) 2011-07-14
US20110183990A1 (en) 2011-07-28
CN104147010A (zh) 2014-11-19
ES2540093T3 (es) 2015-07-08
JP2015057449A (ja) 2015-03-26
PT2515900E (pt) 2015-07-30
IL220152A0 (en) 2012-07-31
HUE026916T2 (en) 2016-08-29
RS54118B1 (sr) 2015-12-31
PL2515900T3 (pl) 2015-10-30
JP2013515007A (ja) 2013-05-02
AP2012006331A0 (en) 2012-06-30
EP2749282B1 (en) 2017-08-09
SG10201408528RA (en) 2015-04-29
ECSP12012004A (es) 2012-08-31
HK1170675A1 (en) 2013-03-08
ES2646603T3 (es) 2017-12-14
SI2515900T1 (sl) 2015-07-31
EA025445B1 (ru) 2016-12-30
PT2749282T (pt) 2017-11-15
DK2515900T3 (en) 2015-07-27
SG181541A1 (en) 2012-07-30
NZ627181A (en) 2016-02-26
US8754087B2 (en) 2014-06-17
CY1116511T1 (el) 2017-03-15
US20130317038A1 (en) 2013-11-28
ZA201204608B (en) 2013-02-27
US20140323493A1 (en) 2014-10-30
UY33119A (es) 2011-07-29
CN102665713A (zh) 2012-09-12
TWI508726B (zh) 2015-11-21
SG10201710751TA (en) 2018-02-27
US9056108B2 (en) 2015-06-16
CN102665713B (zh) 2015-02-18
MX2012007052A (es) 2012-07-30
CA2784028C (en) 2016-08-23
EP2515900B1 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
CL2012001597A1 (es) Formulacion farmaceutica que comprende ranolazina y dronedarona o una sal de esta, y un portador farmaceuticamente aceptable; util para tratar fibrilacion auricular.
PH12017501306A1 (en) Inhibitors of histone demethylases
MX2014015217A (es) Una composicion farmaceutica que contiene acido nicotinico y/o nicotinamida y/o triptofano para influir positivamente en la microbiota intenstinal.
BR112015018418A2 (pt) métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico
BRPI0911444B8 (pt) benzoimidazóis como inibidores de prolil hidroxilase e composição farmacêutica que os compreende
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
CL2016001715A1 (es) Nuevos inhibidores de glutaminasa
CL2014000297A1 (es) Uso de un inhibidores de corrientes "funny" (if) o una de sus sales para utilizar en un metodo de tratamiento y prevencion de la insuficiencia cardiaca en felinos .
CL2012002423A1 (es) Método para tratar lupus nefritis activo que comprende administrar al paciente laquinimod o su sal sódica por vía oral; composición farmacéutica que comprende laquinimod y micofenolato mofetil.
MX2016005394A (es) Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4.
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
CL2012002422A1 (es) Método para tratar artritis por lupus activo que comprende administrar al paciente laquinimod o su sal sódica por vía oral.
CL2011000916A1 (es) Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer.
BR112014028042A2 (pt) inibidores de nampt
CL2015001667A1 (es) Derivados de manosa para tratar infecciones bacterianas.
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
CL2009000316A1 (es) Compuestos derivados de urea de benzomorfanos y sus sales, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de trastornos metabolicos.
BR112013002375A2 (pt) composto, composição farmacêutica, métodos de tratar um indivíduo para um distúrbio proliferativo de induzir a apoptose das células cancerígenas, e de inibir a atividade de cinase em um mamífero, e, processo de preparação de composto
BRPI0819719A2 (pt) Compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e peparações farmacêuticas contendo os mesmos como agente ativo
BR112015017519A2 (pt) compostos e métodos para o tratamento de infecções bacterianas
MX357510B (es) Metodos para tratar ataques de gota.
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
UY32482A (es) Método o sistema que usa biomarcadores para el seguimiento de un tratamiento